The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
Angiogenesis and hepatocellular carcinoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Estimating the world cancer burden: Globocan 2000
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1440 · Cited by 3,721
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Thomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272
Tsujii, M., & DuBois, R. N. (1995) · Cell · doi:10.1016/0092-8674(95)90127-2 · Cited by 2,267
Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162468699 · Cited by 1,989
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., & Folkman, J. (1990) · Nature · doi:10.1038/348555a0 · Cited by 1,299
Benjamin, L. E., Hemo, I., & Keshet, E. (1998) · Development · doi:10.1242/dev.125.9.1591 · Cited by 1,265
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
The Biology of Vascular Endothelial Growth Factor
Ferrara, N. (1997) · Endocrine Reviews · doi:10.1210/er.18.1.4 · Cited by 1,200
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189
Angiostatin induces and sustains dormancy of human primary tumors in mice
O'Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,184
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Lack of Pericytes Leads to Endothelial Hyperplasia and Abnormal Vascular Morphogenesis
Hellström, M., Gerhardt, H., Kalén, M., Li, X., Eriksson, U., Wolburg, H., & Betsholtz, C. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.153.3.543 · Cited by 1,100
Prognostic prediction and treatment strategy in hepatocellular carcinoma
Bruix, J., & Llovet, J. M. (2002) · Hepatology · doi:10.1053/jhep.2002.32089 · Cited by 1,099
Imaging of angiogenesis: from microscope to clinic
McDonald, D. M., & Choyke, P. L. (2003) · Nature Medicine · doi:10.1038/nm0603-713 · Cited by 1,016
Tumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988 · cited 2×
“no drug resistance or toxicity [134–136].”
BackgroundThe Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update
El-Serag, H. B., Davila, J. A., Petersen, N. J., & McGlynn, K. A. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00009 · Cited by 943
Origin of endothelial progenitors in human postnatal bone marrow
Reyes, M., Dudek, A., Jahagirdar, B., Koodie, L., Marker, P. H., & Verfaillie, C. M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214327 · Cited by 887
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Jones, M. K., Wang, H., Peskar, B. M., Levin, E., Itani, R. M., Sarfeh, I. J., & Tarnawski, A. S. (1999) · Nature Medicine · doi:10.1038/70995 · Cited by 827
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731
Vasculogenic Mimicry and Tumor Angiogenesis
Folberg, R., Hendrix, M. J. C., & Maniotis, A. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64739-6 · Cited by 684
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Rafii, S., Lyden, D., Benezra, R., Hattori, K., & Heissig, B. (2002) · Nature Reviews Cancer · doi:10.1038/nrc925 · Cited by 679
Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood
Chang, Y. S., di Tomaso, E., McDonald, D. M., Jones, R., Jain, R. K., & Munn, L. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14608 · Cited by 671
Hepatocellular Carcinoma: An Epidemiologic View
El-Serag, H. B. (2002) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200211002-00002 · Cited by 633
Hamano, Y., Zeisberg, M., Sugimoto, H., Lively, J. C., Maeshima, Y., Yang, C., Hynes, R. O., Werb, Z., Sudhakar, A., & Kalluri, R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00133-8 · Cited by 559
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 522
Colleoni, M., Rocca, A., Sandri, M. T., Zorzino, L., Masci, G., Nolè, F., Peruzzotti, G., Robertson, C., Orlando, L., Cinieri, S., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf013 · Cited by 496
Sidky, Y. A., & Borden, E. C. (1987) · PubMed · Cited by 494
Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature
Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S., & Thorpe, P. E. (1997) · Science · doi:10.1126/science.275.5299.547 · Cited by 477
Oh, P., Li, Y., Yu, J., Durr, E., Krasinska, K. M., Carver, L. A., Testa, J. E., & Schnitzer, J. E. (2004) · Nature · doi:10.1038/nature02580 · Cited by 475
Rodríguez-Manzaneque, J. C., Lane, T. F., Ortega, M. A., Hynes, R. O., Lawler, J., & Iruela-Arispe, M. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171460498 · Cited by 473
Bocci, G., Nicolaou, K. C., & Kerbel, R. S. (2002) · PubMed · Cited by 444
Singh, R. K., Gutman, M., Bucana, C. D., Sanchez, R., Llansa, N., & Fidler, I. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4562 · Cited by 440
Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis
Maeshima, Y., Sudhakar, A., Lively, J. C., Ueki, K., Kharbanda, S., Kahn, C. R., Sonenberg, N., Hynes, R. O., & Kalluri, R. (2002) · Science · doi:10.1126/science.1065298 · Cited by 438
Barbara, L., Benzi, G., Gaiani, S., Fusconi, F., Zironi, G., Siringo, S., Rigamonti, A., Barbara, C., Grigioni, W., Mazziotti, A., et al. (1992) · Hepatology · doi:10.1002/hep.1840160122 · Cited by 431
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 426
A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth
Niethammer, A. G., Xiang, R., Becker, J. C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B. P., & Reisfeld, R. A. (2002) · Nature Medicine · doi:10.1038/nm1202-794 · Cited by 400
Expression of vascular endothelial growth factor in human hepatocellular carcinoma
Yamaguchi, R., Yano, H., Iemura, A., Ogasawara, S., Haramaki, M., & Kojiro, M. (1998) · Hepatology · doi:10.1002/hep.510280111 · Cited by 397
Koga, H., Sakisaka, S., Ohishi, M., Kawaguchi, T., Taniguchi, E., Sasatomi, K., Harada, M., Kusaba, T., Tanaka, M., Kimura, R., et al. (1999) · Hepatology · doi:10.1002/hep.510290355 · Cited by 396
Endostatin's Antiangiogenic Signaling Network
Abdollahi, A., Hahnfeldt, P., Maercker, C., Gröne, H.-J., Debus, J., Ansorge, W., Folkman, J., Hlatky, L., & Huber, P. E. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00102-9 · Cited by 393
Role of Vascular Endothelial Growth Factor in Ovarian Cancer
Mesiano, S., Ferrara, N., & Jaffe, R. B. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65669-6 · Cited by 392
Angiogenesis Ischemic and Neoplastic Disorders
Semenza, G. L. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152418 · Cited by 386
Margolin, K., Gordon, M. S., Holmgren, E., Gaudreault, J., Novotny, W., Fyfe, G., Adelman, D., Stalter, S., & Breed, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.851 · Cited by 364
Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P., & Fidler, I. J. (1999) · PubMed · Cited by 337
The biology of the combretastatins as tumour vascular targeting agents
TOZER, G. M., KANTHOU, C., PARKINS, C. S., & HILL, S. A. (2002) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2002.00211.x · Cited by 335
von Marschall, Z., Scholz, A., Cramer, T., Schafer, G., Schirner, M., Oberg, K., Wiedenmann, B., Hocker, M., & Rosewicz, S. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.437 · Cited by 328
Inhibition of Cell Motility by Interferon
Brouty-Boyé, D., & Zetter, B. R. (1980) · Science · doi:10.1126/science.6154315 · Cited by 326
El-Assal, O. N., Yamanoi, A., Soda, Y., Yamaguchi, M., Igarashi, M., Yamamoto, A., Nabika, T., & Nagasue, N. (1998) · Hepatology · doi:10.1002/hep.510270613 · Cited by 326
Mise, M., Arii, S., Higashituji, H., Furutani, M., Niwano, M., Harada, T., Ishigami, S., Toda, Y., Nakayama, H., Fukumoto, M., et al. (1996) · Hepatology · doi:10.1002/hep.510230309 · Cited by 307
Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Hicklin, D. J., Wu, Y., Yanase, K., Namisaki, T., Yamazaki, M., et al. (2003) · Gut · doi:10.1136/gut.52.9.1347 · Cited by 307
Dredge, K., Marriott, J. B., Macdonald, C. D., Man, H.-W., Chen, R., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600607 · Cited by 296
Regulation of angiogenesis by extracellular matrix
Sottile, J. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2003.07.002 · Cited by 288
Poon, R. T.-P., Ng, I. O.-L., Lau, C., Yu, W.-C., Yang, Z.-F., Fan, S.-T., & Wong, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.089 · Cited by 285
Kuenen, B. C., Rosen, L. S., Smit, E. F., Parson, M., Levi, M. M., Ruijter, R., Huisman, H., Kedde, M. A., Noordhuis, P., van der Vijgh, W. J. F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1657 · Cited by 279
Dixelius, J., Larsson, H., Sasaki, T., Holmqvist, K., Lu, L., Engström, A., Timpl, R., Welsh, M., & Claesson-Welsh, L. (2000) · Blood · doi:10.1182/blood.v95.11.3403 · Cited by 271
Kuo, C. J., Farnebo, F., Yu, E. Y., Christofferson, R., Swearingen, R. A., Carter, R., von Recum, H. A., Yuan, J., Kamihara, J., Flynn, E., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081615298 · Cited by 271
Dinney, C. P., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., BUCANA, C. D., & Fidler, I. J. (1998) · PubMed · Cited by 271
Vascular attack as a therapeutic strategy for cancer
Denekamp, J. (1990) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00046365 · Cited by 264
Antiangiogenic Therapy of a Recurrent Giant Cell Tumor of the Mandible With Interferon Alfa-2a
Kaban, L. B., Mulliken, J. B., Ezekowitz, R. A., Phil, D., Ebb, D., Smith, P. S., & Folkman, J. (1999) · Pediatrics · doi:10.1542/peds.103.6.1145 · Cited by 245
Klement, G. L., Huang, P. H., Mayer, B., Green, S. K., Man, S., Böhlen, P., Hicklin, D. J., & Kerbel, R. S. (2002) · PubMed · Cited by 243
Eder, J. P., Supko, J. G., Clark, J. W., Puchalski, T. A., Garcia-Carbonero, R., Ryan, D. P., Shulman, L. N., Proper, J., Kirvan, M., Rattner, B., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.082 · Cited by 243
Poon, R. T.-P., Ng, I. O.-L., Lau, C., Zhu, L.-X., Yu, W.-C., Lo, C.-M., Fan, S.-T., & Wong, J. (2001) · Annals of Surgery · doi:10.1097/00000658-200102000-00012 · Cited by 240
Park, Y. N., Kim, Y.-B., Yang, K. M., & Park, C. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-1061-ieoveg · Cited by 233
Arii, S., Mise, M., Harada, T., Furutani, M., Ishigami, S., Niwano, M., Mizumoto, M., Fukumoto, M., & Imamura, M. (1996) · Hepatology · doi:10.1002/hep.510240206 · Cited by 231
Fox, S. B., Gasparini, G., & Harris, A. L. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00323-5 · Cited by 230
Brem, S. S., Zagzag, D., Tsanaclis, A. M. C., Gately, S. T., Elkouby, M. P., & Brien, S. (1990) · Europe PMC (PubMed Central) · Cited by 229
Rahman, M. A., Dhar, D. K., Yamaguchi, E., Maruyama, S., Sato, T., Hayashi, H., Ono, T., Yamanoi, A., Kohno, H., & Nagasue, N. (2001) · PubMed · Cited by 223
Poon, R. T. P., Lau, C. P.-Y., Cheung, S., Yu, W., & Fan, S.-T. (2003) · PubMed · Cited by 222
Angiogenesis in chronic inflammatory liver disease
Medina, J., Arroyo, A. G., Sánchez-Madrid, F., & Moreno-Otero, R. (2004) · Hepatology · doi:10.1002/hep.20193 · Cited by 219
Baudelet, C., & Gallez, B. (2002) · Magnetic Resonance in Medicine · doi:10.1002/mrm.10318 · Cited by 218
Reinmuth, N., Liu, W., Jung, Y. D., Ahmad, S. A., Shaheen, R. M., Fan, F., Bucana, C. D., McMahon, G., Gallick, G. E., & Ellis, L. M. (2001) · The FASEB Journal · doi:10.1096/fj.00-0693fje · Cited by 214
Tumor progression: the effects of thrombospondin-1 and -2
Lawler, J., & Detmar, M. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.01.008 · Cited by 210
Chao, Y., Li, C.-P., Chau, G.-Y., Chen, C.-P., King, K.-L., Lui, W.-Y., Yen, S.-H., Chang, F.-Y., Chan, W.-K., & Lee, S.-D. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.10.002 · Cited by 209
Bae, S. H., Jung, E. S., Park, Y. M., Kim, B., Kim, B. K., Kim, D., & Ryu, W. (2001) · PubMed · Cited by 209
Antiangiogenesis signals by endostatin
SHICHIRI, M., & HIRATA, Y. (2001) · The FASEB Journal · doi:10.1096/fj.99-1083com · Cited by 208
Le Pabic, H., Bonnier, D., Wewer, U. M., Coutand, A., Musso, O., Baffet, G., Clément, B., & Théret, N. (2003) · Hepatology · doi:10.1053/jhep.2003.50205 · Cited by 204
Patt, Y. Z., Hassan, M. M., Lozano, R. D., Brown, T. D., Vauthey, J. N., Curley, S. A., & Ellis, L. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.103 · Cited by 200
Microvascular Injury in Pathogenesis of Interferon-Induced Necrosis of Subcutaneous Tumors in Mice
Dvorak, H. F., & Gresser, I. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.7.497 · Cited by 192
Clinical role of MMP‐2/TIMP‐2 imbalance in hepatocellular carcinoma
Giannelli, G., Bergamini, C., Marinosci, F., Fransvea, E., Quaranta, M., Lupo, L., Schiraldi, O., & Antonaci, S. (2002) · International Journal of Cancer · doi:10.1002/ijc.1635 · Cited by 187
Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia‐inducible factor‐1α
Moon, E., Jeong, C., Jeong, J., Rok Kim, K., Yu, D., Murakami, S., Woo Kim, C., & Kim, K. (2004) · The FASEB Journal · doi:10.1096/fj.03-0153fje · Cited by 187
Hamano, Y., Sugimoto, H., Soubasakos, M. A., Kieran, M., Olsen, B. R., Lawler, J., Sudhakar, A., & Kalluri, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3126 · Cited by 185
Mitsuhashi, N., Shimizu, H., Ohtsuka, M., Wakabayashi, Y., Ito, H., Kimura, F., Yoshidome, H., Kato, A., Nukui, Y., & Miyazaki, M. (2003) · Hepatology · doi:10.1053/jhep.2003.50204 · Cited by 183
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo.
Bello, L., Carrabba, G. G., Giussani, C. G., Lucini, V., Cerutti, F., Scaglione, F., Landré, J., Pluderi, M., Tomei, G., Villani, R. M., et al. (2001) · PubMed · Cited by 180
Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
Blakey, D. C., Westwood, F. R., Walker, M., et al. (2002) · PubMed · Cited by 176
Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21 WAF1/CIP1
Zhang, Y., Griffith, E. C., Sage, J., Jacks, T., & Liu, J. O. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6427 · Cited by 175
What brings pericytes to tumor vessels?
Jain, R. K., & Booth, M. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320087 · Cited by 175
Cyclooxygenase-2 expression in hepatocellular carcinoma.
Shiota, G., Okubo, M., Noumi, T., Noguchi, N., Oyama, K., Takano, Y., Yashima, K., Kishimoto, Y., & Kawasaki, H. (1999) · PubMed · Cited by 174
The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing
Bloch, W., Huggel, K., Sasaki, T., Grose, R., Bugnon, P., Addicks, K., Timpl, R., & Werner, S. (2000) · The FASEB Journal · doi:10.1096/fj.00-0490fje · Cited by 171
Anti-angiogenic therapy: Rationale, challenges and clinical studies
Longo, R., Sarmiento, R., Fanelli, M., Capaccetti, B., Gattuso, D., & Gasparini, G. (2002) · Angiogenesis · doi:10.1023/a:1024532022166 · Cited by 170
Yoshii, J., Yoshiji, H., Kuriyama, S., Ikenaka, Y., Noguchi, R., Okuda, H., Tsujinoue, H., Nakatani, T., Kishida, H., Nakae, D., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1537 · Cited by 170
Kern, M. (2002) · Hepatology · doi:10.1016/s0270-9139(02)00094-0 · Cited by 170
Barajas, M., Mazzolini, G., Genové, G., Bilbao, R., Narvaiza, I., Schmitz, V., Sangro, B., Melero, I., Qian, C., & Prieto, J. (2001) · Hepatology · doi:10.1053/jhep.2001.20796 · Cited by 162
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Park, J. W., Kerbel, R. S., Kelloff, G. J., Barrett, J. C., Chabner, B. A., Parkinson, D. R., Peck, J., Ruddon, R. W., Sigman, C. C., & Slamon, D. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0785 · Cited by 159
Dormond, O., Bezzi, M., Mariotti, A., & Rüegg, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209213200 · Cited by 152
Takahashi, N., Haba, A., Matsuno, F., & Seon, B. K. (2001) · PubMed · Cited by 150
TNP-470: an angiogenesis inhibitor in clinical development for cancer
Kruger, E. A., & Figg, W. D. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.6.1383 · Cited by 150
Thalidomide: Emerging Role in Cancer Medicine
Richardson, P. G. G., Hideshima, T., & Anderson, K. C. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104043 · Cited by 141
Logothetis, C. J., Wu, K. K., Finn, L. D., Daliani, D., Figg, W. D., Ghaddar, H. M., & Gutterman, J. U. (2001) · PubMed · Cited by 140
Giannelli, G., Bergamini, C., Fransvea, E., Marinosci, F., Quaranta, V., & Antonaci, S. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780270 · Cited by 139
The first international conference on vascular targeting: meeting overview.
Thorpe, P. E., Chaplin, D. J., & Blakey, D. C. (2003) · PubMed · Cited by 138
Fonsatti, E., Jekunen, A. P., Kairemo, K., et al. (2000) · PubMed · Cited by 135
Lin, S., Lin, C., Hsu, C., Tai, D., Sheen, I., Lin, D., & Liaw, Y. (2004) · Cancer · doi:10.1002/cncr.20004 · Cited by 128
Jin-no, K., Tanimizu, M., Hyodo, I., Nishikawa, Y., Hosokawa, Y., Doi, T., Endo, H., Yamashita, T., & Okada, Y. (1998) · Journal of Gastroenterology · doi:10.1007/s005350050099 · Cited by 126
Membrane associated proteases and their inhibitors in tumour angiogenesis
Noël, A., Maillard, C., Rocks, N., Jost, M., Chabottaux, V., Sounni, N. E., Maquoi, E., Cataldo, D. D., & Foidart, J. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.014472 · Cited by 126
Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma
Stadler, W. M., Kuzel, T. M., Shapiro, C. M., Sosman, J. A., Clark, J. I., & Vogelzang, N. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2541 · Cited by 123
Stoll, B. R., Migliorini, C., Kadambi, A., Munn, L. L., & Jain, R. K. (2003) · Blood · doi:10.1182/blood-2003-02-0365 · Cited by 120
Yamamoto, H., Itoh, F., Adachi, Y., Sakamoto, H., Adachi, M., Hinoda, Y., & Imai, K. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70143-4 · Cited by 119
Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma
Torimura, T., Ueno, T., Kin, M., Harada, R., Taniguchi, E., Nakamura, T., Sakata, R., Hashimoto, O., Sakamoto, M., Kumashiro, R., et al. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.01.027 · Cited by 119
Siméon, A., Emonard, H., Hornebeck, W., & Maquart, F.-X. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00803-1 · Cited by 118
Microvessel density of hepatocellular carcinoma: its relationship with prognosis
Sun, H., Tang, Z., Li, X., Zhou, Y., Sun, B.-R., & Ma, Z. (1999) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050296 · Cited by 118
What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?
Rak, J. W., Yu, J., Kerbel, R. S., & Coomber, B. L. (2002) · PubMed · Cited by 113
Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma
Sugimachi, K., Tanaka, S., Taguchi, K., Aishima, S., Shimada, M., & Tsuneyoshi, M. (2003) · Journal of Clinical Pathology · doi:10.1136/jcp.56.11.854 · Cited by 106
Engleka, K. A., & Maciag, T. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49911-0 · Cited by 104
Moriguchi, M., Nakajima, T., Kimura, H., Watanabe, T., Takashima, H., Mitsumoto, Y., Katagishi, T., Okanoue, T., & Kagawa, K. (2002) · International Journal of Cancer · doi:10.1002/ijc.10740 · Cited by 102
Integrin αvβ3-Mediated Activation of Apoptosis
Brassard, D. L., Maxwell, E., Malkowski, M. G., Nagabhushan, T. L., Kumar, C. C., & Armstrong, L. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4559 · Cited by 100
Yoshiji, H., Kuriyama, S., Yoshii, J., Yamazaki, M., Kikukawa, M., Tsujinoue, H., Nakatani, T., & Fukui, H. (1998) · Hepatology · doi:10.1002/hep.510280607 · Cited by 100
Herbst, R. S., Madden, T. L., Tran, H. T., Blumenschein, G. R., Meyers, C. A., Seabrooke, L. F., Khuri, F. R., Puduvalli, V. K., Allgood, V., Fritsche, H. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.006 · Cited by 100
Clinical Significance of Thrombospondin 1 Expression in Hepatocellular Carcinoma
Poon, R. T. P., Chung, K. K., Cheung, S., Lau, C. P.-Y., Tong, S. W., Leung, K. L., Yu, W. C., Tuszynski, G. P., & Fan, S. T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0435 · Cited by 98
Yamaguchi, R., Yano, H., Nakashima, Y., Ogasawara, S., Higaki, K., Akiba, J., Hicklin, D. J., & Kojiro, M. (2000) · Oncology Reports · doi:10.3892/or.7.4.725 · Cited by 97
Yoshiji, H., Kuriyama, S., Hicklin, D. J., Huber, J., Yoshii, J., Miyamoto, Y., Kawata, M., Ikenaka, Y., Nakatani, T., Tsujinoue, H., et al. (1999) · Hepatology · doi:10.1002/hep.510300509 · Cited by 94
Wilson, S. R., & Burns, P. N. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-15342 · Cited by 91
Joo, Y., Rew, J., Seo, Y., Choi, S.-K., Kim, Y., Park, C.-S., & Kim, S.-J. (2003) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200307000-00009 · Cited by 91
Nonsurgical treatment of hepatocellular carcinoma
Aguayo, Á., & Patt, Y. Z. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90143-5 · Cited by 90
Zhang, L., Yu, D., Hicklin, D. J., Hannay, J. A. F., Ellis, L. M., & Pollock, R. E. (2002) · PubMed · Cited by 90
Chen, C. T., Lin, J., Li, Q., Phipps, S. S., Jakubczak, J. L., Stewart, D. A., Skripchenko, Y., Forry‐Schaudies, S., Wood, J. M., Schnell, C., et al. (2000) · Human Gene Therapy · doi:10.1089/10430340050143417 · Cited by 88
Ching, L.-M., Goldsmith, D., Joseph, W. R., Körner, H., Sedgwick, J. D., & Bc, B. (1999) · PubMed · Cited by 87
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
Ng, S. S. W., Gütschow, M., Weiß, M., Hauschildt, S., Teubert, U., Hecker, T. K., Luzzio, F. A., Kruger, E. A., Eger, K., & Figg, W. D. (2003) · PubMed · Cited by 87
Angiogenesis inhibitors: motivators of metastasis?
Steeg, P. S. (2003) · Nature Medicine · doi:10.1038/nm0703-822 · Cited by 85
Rabascio, C., Muratori, E., Mancuso, P., Calleri, A., Raia, V., Foutz, T. J., Cinieri, S., Veronesi, G., Pruneri, G., Lampertico, P., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0265 · Cited by 85
Hisai, H., Kato, J., Kobune, M., Murakami, T., Miyanishi, K., Takahashi, M., Yoshizaki, N., Takimoto, R., Terui, T., & Niitsu, Y. (2003) · PubMed · Cited by 80
Farnesyltransferase inhibitors: mechanism and applications
Rane, N. S., & Prendergast, G. C. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.12.2105 · Cited by 78
Marler, J. J., Rubin, J. B., Trede, N. S., Connors, S. L., Grier, H. E., Upton, J. M., Mulliken, J. B., & Folkman, J. (2002) · PEDIATRICS · doi:10.1542/peds.109.2.e37 · Cited by 78
Monvoisin, A., Bisson, C., Si‐Tayeb, K., Balabaud, C. P., Desmoulière, A., & Rosenbaum, J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1595 · Cited by 77
Durable Clinical Response of Refractory Hepatocellular Carcinoma to Orally Administered Thalidomide
Patt, Y. Z., Hassan, M. M., Lozano, R. D., Ellis, L. M., Peterson, J. A., & Waugh, K. A. (2000) · American Journal of Clinical Oncology · doi:10.1097/00000421-200006000-00023 · Cited by 70
Musso, O. C., Théret, N., Heljäsvaara, R., Rehn, M., Turlin, B., Campion, J. P., Pihlajaniemi, T. A., & Clément, B. (2001) · Hepatology · doi:10.1053/jhep.2001.23189 · Cited by 69
Wajih, N., & Sane, D. C. (2003) · Blood · doi:10.1182/blood-2002-02-0582 · Cited by 69
Combination antiangiogenic therapy: Increased efficacy in a murine model of Wilms tumor
Soffer, S. Z., Moore, J. T., Kim, E. S., Huang, J., Yokoi, A., Manley, C. A., O’Toole, K., Stolar, C. J. H., Middlesworth, W., Yamashiro, D. J., et al. (2001) · Journal of Pediatric Surgery · doi:10.1053/jpsu.2001.25747 · Cited by 68
Zhang, H., Ozaki, I., Mizuta, T., Matsuhashi, S., Yoshimura, T., Hisatomi, A., Tadano, J., Sakai, T., & Yamamoto, K. (2002) · Cancer · doi:10.1002/cncr.10751 · Cited by 68
Martin, D. C., Sanchez-Sweatman, O. H., Ho, A. T. V., Inderdeo, D. S., Tsao, M., & Khokha, R. (1999) · PubMed · Cited by 68
Nakanishi, K., Fujimoto, J., 植木, 孝., Kishimoto, K., Hashimoto-Tamaoki, T., Furuyama, J.-I., Itoh, T., Sasaki, Y., & Okamoto, E. (1999) · Clinical & Experimental Metastasis · doi:10.1023/a:1006685218766 · Cited by 65
Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity.
Mahasreshti, P. J., Kataram, M., Wang, M. H., Stockard, C. R., Grizzle, W. E., Carey, D. E., Siegal, G. P., Haisma, H. J., Alvarez, R. D., & Curiel, D. T. (2003) · PubMed · Cited by 61
Gorrín-Rivas, M. J., Arii, S., Mori, A., Takeda, Y., Mizumoto, M., Furutani, M., & Imamura, M. (2000) · Annals of Surgery · doi:10.1097/00000658-200001000-00010 · Cited by 59
Shimamura, T., Saito, S., Morita, K., Kitamura, T., Morimoto, M., Kiba, T., Numata, K., Tanaka, K., & Sekihara, H. (2000) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2000.02201.x · Cited by 58
Unexpected Serious Toxicity With Chemotherapy and Antiangiogenic Combinations: Time to Take Stock!
Marx, G. M., Steer, C., Harper, P., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1446 · Cited by 57
Serum endostatin predicts tumor vascularity in hepatocellular carcinoma
Dhar, D. K., Ono, T., Yamanoi, A., Soda, Y., Yamaguchi, E., Rahman, M. A., Kohno, H., & Nagasue, N. (2002) · Cancer · doi:10.1002/cncr.10972 · Cited by 56
Marriott, J. B., Clarke, I., Czajka, A., Dredge, K. S., Childs, K., Man, H., Schafer, P. H., Govinda, S., Muller, G. W., Stirling, D., et al. (2003) · PubMed · Cited by 50
Denda, A., Kitayama, W., Murata, A., Kishida, H., Sasaki, Y., Kusuoka, O., Tsujiuchi, T., Tsutsumi, M., Nakae, D., Takagi, H., et al. (2002) · Carcinogenesis · doi:10.1093/carcin/23.2.245 · Cited by 49
Double target for tumor mass destruction
Saharinen, P., & Alitalo, K. K. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18539 · Cited by 48
Tumor vasculature address book
Rafii, S., Avecilla, S. T., & Jin, D. K. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00278-2 · Cited by 46
Salvage therapy for hepatocellular carcinoma with thalidomide
Wang, T.-E. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i5.649 · Cited by 43
Xia, J., Yang, B., Tang, Z., Sun, F.-X., Xue, Q., & Gao, D. (1997) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01240121 · Cited by 41
Proceedings of the Oxygen Homeostasis/Hypoxia Meeting
Kaufman, B. M., Scharf, O., Arbeit, J. M., Ashcroft, M. A., Brown, J. M., Bruick, R. K., Chapman, J. D., Evans, S. M., Giaccia, A. J., Harris, A. L., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2611 · Cited by 39
Analysis of Matrix Metalloproteinase mRNAs Expressed in Hepatocellular Carcinoma Cell Lines
Kim, J.-H., Kim, T.-H., Jang, J.-W., Jang, Y. J., Lee, K., & Lee, S. (2001) · Molecules and Cells · doi:10.1016/s1016-8478(23)17059-2 · Cited by 36
Teicher, B. A., Menon, K., Alvarez, E., Liu, P., Shih, C., & Mm, F. (2001) · PubMed · Cited by 36
The promise of gene therapy in gastrointestinal and liver diseases
Prìeto, J., Herráiz, M., Sangro, B., Qian, C., Mazzolini, G., Melero, I., & Ruiz, J. (2003) · Gut · doi:10.1136/gut.52.suppl_2.ii49 · Cited by 35
Liétard, J., Théret, N., Rehn, M., Musso, O. C., Dargère, D., Pihlajaniemi, T. A., & Clément, B. (2000) · Hepatology · doi:10.1053/jhep.2000.20066 · Cited by 30
Wu, H., Feng, G., Liang, H., Zheng, C., & Li, X. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i6.813 · Cited by 28
Tran, P.-L., Vigneron, J., Péricat, D., Dubois, S., Cazals-Hatem, D. L., Hervy, M., DeClerck, Y. A., Degott, C., & Auclair, C. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700592 · Cited by 27
Mauriz, J. L., Linares, P., Macías, R. I. R., Jorquera, F., Honrado, E., Olcoz, J. L., González, P., & González‐Gallego, J. (2003) · Free Radical Research · doi:10.1080/1071576031000136577 · Cited by 24
Tai, K., Chen, P., Chen, D., & Hwang, L. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.376 · Cited by 24
Péron, J., Couderc, B. C., Rochaix, P., et al. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2003.03295.x · Cited by 22
Mallery, S. R., Morse, M. A., Wilson, R. F., Pei, P., Ness, G. M., Bradburn, J. E., Renner, R. J., Schuller, D. E., & Robertson, F. M. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10489 · Cited by 18
Early Changes in Gene Expression During Liver Regeneration: What Do They Mean?
Dubois, R. D. (1990) · Hepatology · doi:10.1002/hep.1840110626 · Cited by 18
[Role of hepatic stellate cells in the angiogenesis of hepatoma].
Jung, J.-O., Gwak, G., Lim, Y., Kim, C. Y., & Lee, H.-S. (2003) · PubMed · Cited by 14
Cited by
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“(1) Vascular growth factor (VEGF) signaling is the cornerstone of angiogenesis in HCC, and high level amplifications have been identified [175,307].”
BackgroundLiu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., Wilhelm, S., Lynch, M., & Carter, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1377 · Cited by 1,536
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Liver sinusoidal endothelial cells: Physiology and role in liver diseases
Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., & Rautou, P.-E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.009 · Cited by 1,047
Metadata
- Authors
- Semela, D., & Dufour, J.-F.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2004-11
- Volume
- 41
- Issue
- 5
- Pages
- 864-880
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2163382189
- Cited by
- 372
- References
- 190
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.